Constant Companion partners with Canary Speech to help diagnose behavioral health trends
SARASOTA, Florida. and PROVO, Utah, April 22, 2021 /PRNewswire/ — Constant Companion and Canary Speech have formed a new strategic partnership to explore how speech technology can be used to identify human conditions in specific populations. These pioneering companies have a common goal to use this advanced technology to provide better patient care and better outcomes for seniors.
Constant Companion will use its patented, voice-enabled, AI-powered platform used by seniors and their caregivers to facilitate better communication and monitoring. Canary Speech will analyze the data with its patented digital speech biomarker technology, which is used to diagnose behavioral disorders and other diseases.
Ultimately, the study, which will be conducted with informed consent using anonymized data, will improve the information clinical teams have about their patients and improve the quality of care.
Constant Companion’s mission is to improve people’s lives. They do this by using empathy, data and voice technology to create experiences that keep customers more engaged, connected and protected, 24/7. They are integrating their AI-powered, voice-enabled, and HIPAA-compliant platform into popular smart speakers facilitating better communication and monitoring for seniors, caregivers, and families.
Canary Speech is transforming the use of speech analysis technology to benefit the diagnosis and treatment of health conditions and behavioral diseases. Canary’s HIPAA-compliant technology offers a new approach to capturing and measuring critical data, enabling the replacement of today’s subjective measures of behavioral health with a standard approach to objectively measuring a range of voice data points. Canary Speech has commercialized a hands-on approach to assessments, screening and diagnosis, and digitally communicates results to a clinical team.
The partnership will help both companies put measurements on human conditions and define which models reveal certain diseases. Canary Speech will analyze both a patient’s words and the emotions they speak with, to capture critical mental and behavioral health data that can help identify depression, anxiety or stress. The company has identified more than 2,500 biomarkers in speech that are consistent for disease in a range of individuals.
“Today marks an important milestone for AI-powered voice technology in the future of healthcare innovation,” said Marc Gray, founder and CEO of Constant Companion. “Healthcare requires human-centric, value-driven solutions built on trust and connection. The partnership between Canary Speech and Constant Companion helps deliver that at scale.”
“This is truly a game-changing partnership that will allow us to analyze data that will help advance the care of our aging population,” said Henry O’Connell, founder and CEO of Canary Speech. “Our ultimate goal is to study these biomarkers and increase the quality of care that clinical teams provide to patients.”
The study will follow strict HIPAA guidelines and will only be conducted with informed patient consent. Throughout the study, data captured will be anonymized so that patients can remain anonymous. However, both teams will still be able to determine the impact that Constant Companion and their voice technologies have on seniors.
ABOUT CONSTANT COMPANION
About: Constant Companion keeps people engaged, connected and protected 24/7. The company’s voice-activated systems for healthcare, home care and senior living communities provide a more accessible means of communication and provide always-there care. Constant Companion systems are simple and easy to use, fun, entertaining and affordable, all without giving up a little privacy. Using several popular voice assistant platforms, Constant Companion has created the only HIPAA-compliant AI-based technology supporting healthcare and home care. Their systems are used in more than 500 counties nationwide. For more information, visit www.constantcompanion.com.
ABOUT THE CANARY SPEECH
Canary Speech is the global industry leader in digital speech biomarkers by performing real-time speech analysis of as little as 40 seconds of speech using smart devices. By advancing speech and language applications for the hospital, health and wellness, and pharmaceutical markets, the UtahThe New York-based company improves patient care and outcomes by improving quality of care and quality of life with its patented AI voice technology. Canary Speech technology also offers the possibility of improving telemedicine and remote medical services. For more information visit www.canaryspeech.com
Constant Companion SOURCE